Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

DRUG3 trials

Sponsors

Shanghai Yunying Medical Technology

Conditions

Advanced CancerBone TumorCervical CancerEndometrial CancerOsteosarcomaSarcomaSarcoma,Soft TissueSoft Tissue Sarcoma

Early Phase 1

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

RecruitingNCT05812677

Shanghai Yunying Medical TechnologyAdvanced Cancer, Cervical Cancer, Endometrial Cancer

Start: 2023-02-06End: 2026-02-06Target: 20Updated: 2023-04-14

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors

RecruitingNCT05851456

Shanghai Yunying Medical TechnologyBone Tumor, Osteosarcoma, Sarcoma +1

Start: 2023-04-10End: 2026-04-30Target: 20Updated: 2023-05-09

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

RecruitingNCT06171282

Shanghai Yunying Medical TechnologyBone Tumor, Osteosarcoma, Sarcoma +1

Start: 2023-07-12End: 2026-07-12Target: 9Updated: 2023-12-14